Conventional antipsychotic medications for schizophrenia

被引:141
|
作者
Dixon, LB
Lehman, AF
Levine, J
机构
[1] UNIV MARYLAND, CTR MENTAL HLTH SERV RES, BALTIMORE, MD 21201 USA
[2] NATHAN S KLINE INST PSYCHIAT RES, ORANGEBURG, NY 10962 USA
[3] NYU, SCH MED, NEW YORK, NY USA
关键词
D O I
10.1093/schbul/21.4.567
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This article reviews the existing evidence for the efficacy and effectiveness of conventional antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are their efficacy for acute symptom episodes and. for long-term maintenance therapy, differential efficacy among medications, the gap between research-based efficacy rates;ind effectiveness rates in practice, dosing strategies, and the treatment of first-episode cases. Evidence for efficacy is overwhelming for reduction of positive symptoms but quite limited for other outcomes. Effectiveness in practice may be substantially less than efficacy in clinical trials, perhaps owing to patient heterogeneity, prescribing practices, and noncompliance. First-episode patients should be treated with antipsychotic medication, but perhaps at lower dosages, with consideration of a gradual decrease or discontinuation at 6 months to 1 year.
引用
收藏
页码:567 / 577
页数:11
相关论文
共 50 条
  • [21] The Effect of Antipsychotic Medications on Acoustic Startle Latency in Schizophrenia
    Duncan, Erica
    Hasenkamp, Wendy
    Gross, Robin
    Cuthbert, Bruce
    Green, Amanda
    Swails, Lisette
    Lewison, Barbara
    Boshoven, William
    Keyes, Megan
    BIOLOGICAL PSYCHIATRY, 2015, 77 (09)
  • [22] Latency of Acoustic Startle in Schizophrenia: Effects of Antipsychotic Medications
    Duncan, Erica
    Hasenkamp, Wendy
    Gross, Robin
    Cuthbert, Bruce
    Green, Amanda
    Swails, Lisette
    Lewison, Barbara
    Boshoven, William
    Keyes, Megan
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S456 - S457
  • [23] Diabetes mellitus in patients with schizophrenia is not related to antipsychotic medications
    Prosperini, P
    Olgiati, P
    D'Innella, P
    Torre, E
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 365 - 365
  • [24] Severity in schizophrenia patients receiving atypical antipsychotic medications
    Fatmi, Syed Meraj Alam
    Koul, Rakesh
    Prakash, Suruchi
    Ayub, Sheenam
    BIOINFORMATION, 2022, 18 (12) : 1154 - 1158
  • [25] Specific antipsychotic medications - a treatment for aggressive behaviour in schizophrenia?
    Patel, K.
    Khalid, E.
    Cree, A.
    Sainz-Fuertes, R.
    Shortt, M.
    Mak, T.
    Alderton, J.
    Hodgins, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S73 - S74
  • [26] Emerging roles for novel antipsychotic medications in the treatment of schizophrenia
    Andersson, C
    Chakos, M
    Mailman, R
    Lieberman, J
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1998, 21 (01) : 151 - +
  • [27] Use patterns for antipsychotic medications in Medicaid patients with schizophrenia
    McCombs, JS
    Nichol, MB
    Stimmel, GL
    Shi, JH
    Smith, RR
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 5 - 11
  • [28] Measuring neuropsychological change in schizophrenia with novel antipsychotic medications
    Purdon, SE
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2000, 25 (02): : 108 - 116
  • [29] The effect of antipsychotic medications on acoustic startle latency in schizophrenia
    Fargotstein, Molly
    Hasenkamp, Wendy
    Gross, Robin
    Cuthbert, Bruce
    Green, Amanda
    Swails, Lisette
    Lewison, Barbara
    Boshoven, William
    Keyes, Megan
    Duncan, Erica
    SCHIZOPHRENIA RESEARCH, 2018, 198 : 28 - 35
  • [30] Antipsychotic medications and progressive brain tissue loss in schizophrenia
    Andreasen, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 38 - 38